Focus on sarcomas  by Mackall, Crystal L et al.
F O C U S
CANCER CELL : SEPTEMBER 2002 · VOL. 2 · COPYRIGHT © 2002 CELL PRESS 175
Focus on sarcomas
Crystal L. Mackall,1 Paul S. Meltzer,2 and Lee J. Helman1,3
1National Cancer Institute, Pediatric Oncology Branch
2National Human Genome Research Institute, Cancer Genetics Branch
National Institutes of Health, Bethesda, Maryland 20892
3Correspondence: helmanl@nih.gov
Introduction and epidemiology
Sarcomas in general are rare tumors, accounting for less than
5% of adult neoplasms and less than 20% of pediatric malig-
nancies. They represent a much larger proportion of pediatric
malignancies compared to their proportional representation in
adults, although their absolute numbers are much higher in
adults. Several of these tumors including, osteogenic sarcoma,
Ewing’s sarcoma, and synovial sarcoma, have peak incidences
in adolescents and young adults, while other tumors such as
chondrosarcomas have a peak incidence in patients over the
age of 65. These tumors are derived from mesodermal or ecto-
dermal germ layers, in contradistinction to the more common
carcinomas, which are typically derived from endoderm.
Sarcomas are histologically diverse, and although the histogen-
esis of some sarcomas is unknown, others exhibit features
resembling normal connective tissue elements, such as bone,
cartilage, fat, and muscle, from which they appear to rise (see
Figure 1). The relative rarity and diversity of histologies have
hindered large randomized treatment studies. In general, the
etiology of these tumors is obscure, and the overwhelming
majority of sarcomas appear to occur through sporadic muta-
tions. However, there are currently four known familiar cancer
syndromes associated with sarcomas. Patients with germline
mutations of the retinoblastoma (RB) gene have a much higher
frequency of osteosarcomas (Abramson et al., 1984). Patients
with Li-Fraumeni syndrome and germline mutations of the p53
gene (Li and Fraumeni, 1969; Malkin et al., 1990) have an
increased incidence of a variety of sarcomas typically diag-
nosed before the age of 45. Another sarcoma, malignant
peripheral nerve sheath tumor, or MPNST, occurs in up to 50%
of cases in the setting of neurofibromatosis 1 (NF-1) that is
associated with germline loss of the NF1 gene (King et al.,
2000). Finally, a recently described familial gastrointestinal stro-
mal tumor (GIST) syndrome was described in a kindred with
germline mutations of c-kit (Nishida et al., 1998). Known envi-
ronmental risk factors for sarcoma development include ionizing
irradiation, which is associated with the development of a vari-
ety of sarcomas, and vinyl chloride, which is an established
cause of hepatic angiosarcoma.
Genetics
A major recent advance in our understanding of sarcomas has
been the identification of specific genetic abnormalities corre-
sponding to specific histologic subtypes of sarcomas. This
understanding has led to new specific diagnostic entities, as
well as new approaches to the treatment of these tumors.
Rather than treating all sarcomas in a uniform fashion, each
specific genetic/histologic subtype should be considered a
unique therapeutic target. Of particular interest to the molecular
biologist, a subset of sarcomas is cytogenetically relatively sim-
ple and exhibits reciprocal chromosome translocations resulting
in the formation of fusion genes (Table 1). Not only have these
translocations provided new highly specific diagnostic markers,
but they also hold the key to new insights into the biology of
these tumors. It appears clear that these disease-specific
translocations are necessary for tumorigenesis, but they may
not be sufficient. Other “second hits” and/or a uniquely permis-
sive environment present in an early mesenchymal stem and/or
progenitor cell may be necessary for malignant transformation
(Deneen and Denny, 2001). One model holds that a primary
effect of the sarcoma-specific translocations is to dictate lin-
eage commitment and/or impair differentiation, as exemplified
by the myogenic commitment of NIH-3T3 cells following expres-
sion of the PAX3-FKHR translocation which is found in alveolar
rhabdomyosarcoma (Khan et al., 1999), thus expanding the
pool of cells that may be susceptible to the “second hit.” Similar
models are emerging in leukemia biology wherein specific
translocations induce differentiation arrest at distinct stages of
hematopoiesis but second genetic events are required for the
full induction of the leukemic state (Dash et al., 2002; Kelly et
al., 2002).
A second group of sarcomas (exemplified by osteosarcoma
and leiomyosarcoma) is characterized by a chaotic karyotype
and the lack of distinct fusion genes. Mutations in the tumor sup-
pressor genes Rb and p53 are found with varying frequency in
both groups, but it appears that disturbances in mechanisms
that regulate genomic integrity are a common feature of the
cytogenetically complex sarcomas. Aside from the transloca-
tions, few initiating events in sarcomas have been described.
Amplification of the cell-cycle-related genes CDK4 and MDM2
occurs sporadically in various sarcomas, but otherwise little is
known of cooperating genes that contribute to tumor progres-
sion. Obtaining a more comprehensive description of the genes
involved in the initiation and progression of sarcomas remains a
major goal for future research. It is of interest to note that two
common benign mesenchymal tumors, leiomyomas and lipo-
mas, have a high incidence of recurrent rearrangements of
chromosome 12q involving the high mobility protein group gene
HMGIC (Schoenmakers et al., 1995), but these translocations
are not seen in the corresponding leiomyosarcomas or liposar-
comas, indicating that the benign tumors are not precursor
lesions in these cases. In contrast, plexiform neurofibromas,
benign tumors associated with NF-1 syndrome, have loss of
neurofibromin expression, and this does appear to be the pre-
cursor lesion in MPNST occurring in the setting of NF-1. In addi-
tion, sarcoma genetics may yield important insights into the
stem cell biology of connective tissue, which could potentially
impact novel areas of biomedical research such as tissue engi-
neering.
Conventional diagnostics and therapeutics
Until recently, the diagnosis of a sarcoma depended solely upon
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histopathologic review of a biopsy sample, and this remains an
important part of the overall diagnostic evaluation. The tumor is
deemed to be malignant based on standard criteria such as
anaplasia and invasion, among others, and tumors are given
specific diagnoses based upon assignment to a particular differ-
entiation lineage (fat, cartilage, or bone, for example).
Differentiation lineage is generally determined based upon his-
tologic appearance using both H&E staining and immunohisto-
chemical stains using lineage-specific antibodies. But, even
with the use of these techniques, the specific diagnosis of a sar-
coma can often be difficult, and the addition of cytogenetic and
molecular cytogenetic techniques has proven to be particularly
useful in the final classification of these difficult cases. In those
tumors with reciprocal translocations generating tumor-specific
fusion proteins, numerous studies have confirmed the utility of
applying RT-PCR techniques to aid in diagnosis (Bennicelli and
Barr, 2002).
Staging of sarcomas is determined by the extent of disease
and the tumor grade. Extent of disease is related to tumor size,
depth of invasion, and the presence or absence of metastases.
Unlike carcinomas, which typically spread via lymphatics, sar-
comas spread hematogenously, with the lungs and bone being
the most common sites of metastasis. High mitotic activity and
necrosis within a tumor leads to the assignment of a high grade.
While low-stage tumors are generally treated with surgical
resection alone and high-stage tumors are treated with adjuvant
therapy (e.g., radiation therapy and/or chemotherapy), it is
important to note that histologic subtype plays a primary role in
determining the effectiveness of adjuvant therapy and overall
outcome. For example, adjuvant therapy has shown dramatic
success in pediatric sarcomas (e.g., Ewing’s sarcoma,
osteosarcoma, and rhabdomyosarcoma), where survival has
increased from <20% to approximately 70% by the addition of
cytotoxic chemotherapy to local therapies (Arndt and Crist,
Figure 1. Schematic model for differentiation of mesenchymal tissues and sarcoma tumorigenesis
Boxes represent progenitor cells for each lineage shown. Solid lines designate normal differentiation and dotted lines represent potential pathways for sar-
coma tumorigenesis. For some sarcomas (e.g., MPNST, SS, and Ewings), the exact lineage remains unknown. ICC = interstitial cells of Cajal.
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1999). In other sarcomas, such as synovial sarcoma, MPNST,
and myxoid liposarcoma, clinical responses to chemotherapy
are frequently seen, but a clear survival advantage has not
been demonstrated (Bramwell et al., 1994). Still other sarco-
mas, such as nonuterine leiomyosarcomas, alveolar soft-part
sarcomas, and clear-cell sarcomas, only rarely respond to cyto-
toxic chemotherapy, and thus new therapeutic targets are criti-
cally needed (Singer et al., 2000).
New targets and novel therapies
Because causal-unique molecular genetic alterations have
been identified in a number of these tumors, it is predicted that
effective targeted therapies could be developed for individual
histologies. Gastrointestinal stromal tumors (GISTs) provide a
specific example of how molecular characterization of a tumor
entity led to both a new diagnostic category of tumor and a new
and effective targeted therapy in a tumor that previously had no
effective therapy. GISTs had previously been referred to as gas-
trointestinal leiomyosarcomas, emphasizing a presumed
smooth muscle origin based upon histopathology. But unlike
uterine leiomyosarcomas that may respond to cytotoxic
chemotherapy, “leiomyosarcomas” of the GI-tract are almost
uniformly unresponsive to chemotherapy. In 1998, activating
mutations in the c-kit oncogene were identified as a distinguish-
ing feature of these tumors (Hirota et al., 1998). Within two
years, it was determined that these tumors likely arise from the
interstitial cells of Cajal, cells that coordinate peristaltic activity
throughout the GI tract and that appear to depend on c-kit sig-
naling for normal differentiation. These tumors were renamed
GISTs, and over 90% have now been shown to harbor somatic
c-kit mutations (Berman and O’Leary, 2001; Rubin et al., 2001).
Of note, true leiomyosarcomas of the GI tract are much rarer
than GISTs and do not have any evidence of c-kit mutations.
The observation that somatic gain-of-function mutations in the
c-kit tyrosine kinase characterized GIST suggested that consti-
tutive activation of c-kit was the critical event in the malignant
transformation of this tumor. This was confirmed by evidence
that the tyrosine kinase inhibitor STI571 induced apoptosis of
GIST cell lines in vitro (Tuveson et al., 2001) and induced dra-
matic clinical responses as well (van Oosterom et al., 2001).
The c-kit specificity of this activity is extrapolated from the evi-
dence that rare GISTs without activating c-kit mutations show
much less sensitivity to STI571. Thus, identification and target-
ing of critical genetic alterations in GIST have dramatically
changed both the classification and clinical outcome of this dis-
ease (Dematteo et al., 2002).
The identification of similar critical targets in other sarco-
mas remains the challenge of the future. Another sarcoma, der-
matofibrosarcoma protuberans, may also respond to STI571,
since the tumor-specific translocation in this tumor leads to
overexpression of PDGFβ, whose receptor tyrosine kinase is
also inhibited by STI571 (See Table 1). As noted in the introduc-
tion, MPNST tumors are associated with homozygous loss of
the NF1 gene, often occurring in the setting of NF1 with
germline loss of one NF1 allele. The NF1 gene encodes for a
protein known as neurofibromin, which shares homology with
the Ras-GAP protein. Ras-GAP inhibits Ras signaling, and the
presumption is that loss of NF1 may enhance Ras activity in
MPNST tumors.Thus, the use of agents targeting the Ras path-
way has been of interest in these tumors, and there is an ongo-
ing study evaluating a farnesyl transferase inhibitor (targeting
Ras) in plexiform neurofibromas, a precursor lesion for MPNST.
Importantly, however, even in cases where a causal genetic
alteration has been described, the critical downstream targets
responsible for initiating and/or maintaining the malignant phe-
notype often remain elusive. For example, in Ewing’s sarcoma,
the t(11;22) is generally accepted as the necessary and essen-
tial genetic event that initiates and maintains this sarcoma, but
pertinent downstream targets that could be inhibited therapeuti-
cally have remained elusive (Arvand and Denny, 2001). In the
absence of unique causal targets, current research is aimed at
targeting growth or death pathways that have some impact on
tumor growth, either alone or in concert with other therapies. For
example, despite an absence of constitutive c-kit activation,
Ewing’s sarcomas often express c-kit, and SCF-mediated sig-
naling has been implicated as one of many growth loops
involved in survival of this tumor (Landuzzi et al., 2000). STI571
inhibits growth of this tumor, but at higher concentrations than
those required by GIST.Whether inhibition of the SCF-mediated
growth factor pathway or inhibition of another, less sensitive
kinase is responsible for STI571’s effects in Ewing’s sarcoma is
currently under study. In either case, this example illustrates the
concept that even secondary growth factor-mediated pathways
may render tumors sensitive to the effects of targeted therapeu-
tics (Heinrich et al., 2002).
Another potentially promising approach is the activation of
death-receptor pathways in sarcomas. Proof-of-principle that
such agents can induce selective tumor kill comes from the effi-
cacy of limb perfusion using TNFα with cytotoxic agents to con-
vert unresectable sarcomas to resectable (Lejeune et al.,
2000). Indeed, these trials have led to the approval of TNFα in
Europe as a therapeutic agent for unresectable limb sarcoma.
While toxicity limits systemic use of TNFα, another member of
the TNF family, TRAIL/Apo2L, shows a higher level of tumor
specificity (Ashkenazi et al., 1999). TRAIL/Apo2L induces cell
death in a variety of sarcomas—including Ewing’s sarcoma
(Kontny et al., 2001), osteosarcoma (Evdokiou et al., 2002), and
rhabdomyosarcoma (Petak et al., 2000)—either alone or in con-
Table 1. Sarcoma translocations resulting in gene fusions
Tumor Translocation Genes
Ewings sarcoma t(11:22)(q24;q12) EWSR1-FLI1
t(21;22)(q22;q12) EWSR1-ERG
t(7;22)(p22;q12) EWSR1-ETV1
t(17;22)(q21;q12) EWSR1-ETV4
t(2;22)(q33;q12) EWSR1-FEV
clear cell sarcoma t(12;22)(q13;q12) EWSR1-ATF1
desmoplastic small t(11;22)(p13:q12) EWSR1-WT1
round cell tumor
myxoid t(9;22)(q22-31;q11-12) EWSR1-NR4A3
chondrosarcoma
myxoid liposarcoma t(12:16)(q13;p11) FUS-DDIT3
t(12;22)(q13;q12) EWSR1-DDIT3
Alveolar t(2:13)(q35:q14) PAX3-FOXO1A
rhabdomyosarcoma t(1:13)(p36:q14) PAX7-FOXO1A
Synovial sarcoma t(X;18)(p11:q11) SYT-SSX
Dermatofibrosarcoma t(17:22)(q22:q13) COL1A1-PDGFB
protuberans
Congenital fibrosarcoma t(12;15)(p13;q25) ETV6-NTRK3
Inflammatory myofibroblastic 2p23 rearrangements TMP3-ALK;
tumor TMP4-ALK
Alveolar soft part sarcoma t(X;17)(p11.2;q25) ASPL-TFE3
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cert with immunomodulating or cytotoxic therapies. Clinical
agents that can ligate the death domain containing TRAIL
receptors currently are being developed.
Future challenges
In summary, sarcomas represent a heterogeneous group of dis-
eases, each with a unique and complex pathway to carcinogen-
esis. The challenge of the next decade will be to define sarco-
mas according to their unique molecular alterations and to treat
them accordingly. The implementation of genomic technologies
such as microarray analysis will facilitate this biologically based
tumor classification and accelerate drug-target discovery
(Allander et al., 2001; Khan et al., 2001).The intriguing possibil-
ity that identification of critical genetic events will lead to specif-
ic, nontoxic therapies for individual tumors has led to enthusi-
asm within the scientific community for dissecting the genomic
and proteomic pathways that fuel these tumors. The challenge
is finding not one, but many “magic bullets” that can effectively
target the numerous and varied sarcomas.
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